Evidence map›Paper›PMID 26351689›Full record

ArticleProceedings of the National Academy of Sciences of the United States of America2015

Broad and efficient control of major foodborne pathogenic strains of Escherichia coli by mixtures of plant-produced colicins.

Steve Schulz, Anett Stephan, Simone Hahn, Luisa Bortesi, Franziska Jarczowski, Ulrike Bettmann, Anne-Katrin Paschke, Daniel Tusé, Chad H Stahl, Anatoli Giritch and 1 more

Open access · bronzeAbstract read
In one paragraph

Article in Proceedings of the National Academy of Sciences of the United States of America, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers.

0numbers the graph read from it
0cells of the map it votes in
37citing papers in PubMed
6.8field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

37 citing papers in PubMed, 71 citations in OpenAlex.

  1. Plant-Based Systems for Producing Therapeutic Proteins: Current Status and Future Prospects.BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy · 2026
    Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Life (Basel, Switzerland) · 2022
    Article
  9. EngineeringAIChE journal. American Institute of Chemical Engineers · 2021
    Article
  10. The Biology of Colicin M and Its Orthologs.Antibiotics (Basel, Switzerland) · 2021
    Review
  11. Review
  12. Article
  13. RobustFrontiers in bioengineering and biotechnology · 2021
    Article
  14. Article
  15. Review
  16. Article
  17. Review
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

11 authors at 3 institutions in 2 countries.

Steve SchulzNomad Bioscience GmbH, Biozentrum Halle, D-06120 Halle (Saale), Germany;
Anett StephanNomad Bioscience GmbH, Biozentrum Halle, D-06120 Halle (Saale), Germany;
Simone HahnNomad Bioscience GmbH, Biozentrum Halle, D-06120 Halle (Saale), Germany;
Luisa BortesiNomad Bioscience GmbH, Biozentrum Halle, D-06120 Halle (Saale), Germany;
Franziska JarczowskiIcon Genetics GmbH, Biozentrum Halle, D-06120 Halle (Saale), Germany;
Ulrike BettmannIcon Genetics GmbH, Biozentrum Halle, D-06120 Halle (Saale), Germany;
Anne-Katrin PaschkeIcon Genetics GmbH, Biozentrum Halle, D-06120 Halle (Saale), Germany;
Daniel TuséDT/Consulting Group, Sacramento, CA 95818;
Chad H StahlDepartment of Animal and Avian Sciences, University of Maryland, College Park, MD 20742.
Anatoli GiritchNomad Bioscience GmbH, Biozentrum Halle, D-06120 Halle (Saale), Germany; giritch@nomadbioscience.com.
Yuri GlebaNomad Bioscience GmbH, Biozentrum Halle, D-06120 Halle (Saale), Germany;
Nomad Bioscience (Germany) · DEBioSolutions Halle (Germany) · DEUniversity of Maryland, College Park · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Enterohemorrhagic Escherichia coli (EHEC) is one of the leading causes of bacterial enteric infections worldwide, causing ∼100,000 illnesses, 3,000 hospitalizations, and 90 deaths annually in the United States alone. These illnesses have been linked to consumption of contaminated animal products and vegetables. Currently, other than thermal inactivation, there are no effective methods to eliminate pathogenic bacteria in food. Colicins are nonantibiotic antimicrobial proteins, produced by E. coli strains that kill or inhibit the growth of other E. coli strains. Several colicins are highly effective against key EHEC strains. Here we demonstrate very high levels of colicin expression (up to 3 g/kg of fresh biomass) in tobacco and edible plants (spinach and leafy beets) at costs that will allow commercialization. Among the colicins examined, plant-expressed colicin M had the broadest antimicrobial activity against EHEC and complemented the potency of other colicins. A mixture of colicin M and colicin E7 showed very high activity against all major EHEC strains, as defined by the US Department of Agriculture/Food and Drug Administration. Treatments with low (less than 10 mg colicins per L) concentrations reduced the pathogenic bacterial load in broth culture by 2 to over 6 logs depending on the strain. In experiments using meats spiked with E. coli O157:H7, colicins efficiently reduced the population of the pathogen by at least 2 logs. Plant-produced colicins could be effectively used for the broad control of pathogenic E. coli in both plant- and animal-based food products and, in the United States, colicins could be approved using the generally recognized as safe (GRAS) regulatory approval pathway.

Indexed as

Amino Acid SequenceAnimalsBeta vulgarisColicinsElectrophoresis, Polyacrylamide GelEscherichia coli InfectionsEscherichia coli O157FishesFood MicrobiologyMeatMolecular Sequence DataNicotianaPlants, EdiblePlants, Genetically ModifiedRecombinant ProteinsSpinacia oleraceaColicinsRecombinant ProteinsantimicrobialscolicinEHECfood safetyplant-made recombinant proteins

Identifiers

PMID26351689
PMCPMC4603501
OpenAlexW2143494574

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.